Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | HPGD | P15428 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | CASP1 | P29466 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | CASP7 | P55210 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | ANO1 | Q5XXA6 | 2/20 | 0.36 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | APEX1 | P27695 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.35 |
| ▸ | GLA | P06280 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14503016 | 0.82 | RIPK1 (0.40) | ALDH1A1SMN1; SMN2HPGDKDM4EGAA | |
| SCHEMBL9284100 | 0.81 | KDM4E (0.51) | ALDH1A1SMN1; SMN2HPGDKDM4EGAA | |
| SCHEMBL9257568 | 0.79 | ALDH1A1 (0.39) | ALDH1A1SMN1; SMN2HPGDKDM4EGAA | |
| SCHEMBL164943 | 0.78 | YTHDC1 (0.37) | ALDH1A1KDM4EL3MBTL1PRKCI | |
| SCHEMBL7576218 | 0.75 | PLCG1 (0.42) | ALDH1A1SMN1; SMN2HPGDKDM4EGAA | |
| SCHEMBL163224 | 0.73 | SMN1; SMN2 (0.42) | ALDH1A1SMN1; SMN2KDM4ENPC1CASP1 | |
| SCHEMBL4605525 | 0.73 | SMN1; SMN2 (0.48) | ALDH1A1SMN1; SMN2KDM4EGAANPC1 | |
| SCHEMBL163050 | 0.73 | SMN1; SMN2 (0.58) | ALDH1A1SMN1; SMN2KDM4EGAANPC1 | |
| SCHEMBL31426964 | 0.73 | ANO1 (0.40) | SMN1; SMN2HPGDANO1RIPK1POLB | |
| SCHEMBL30853475 | 0.73 | SMN1; SMN2 (0.48) | ALDH1A1SMN1; SMN2KDM4EGAANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9856210-B2 | Pharmaceutical composition for prevention and treatment of amyotrophic lateral sclerosis | KYOTO UNIVERSITY (JP) | 2018-01-02 | — | — | US | disclosed |
| EP-2611437-B1 | PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | UNIV KYOTO (JP) | 2017-03-29 | — | — | EP | disclosed |
| US-20130225642-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | KYOTO UNIVERSITY (JP) | 2013-08-29 | — | — | US | disclosed |
| EP-2611437-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | Kyoto University (JP) | 2013-07-10 | — | — | EP | disclosed |
| WO-2012029994-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | KYOTO UNIVERSITY (JP) | 2012-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130225642-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | SMN1; SMN2, SOD1, SOD3 | ALDH1A1 1667/4885SMN1; SMN2 1/4885HPGD 2718/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.